

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Lymphocyte choriomeningitis virus (LCMV)-based vaccine vectors	<p>Recombinant LCMV vectors expressing antigens could provide a vaccine platform for infectious diseases or cancer. In mice, injection of a recombinant LCMV vector expressing ovalbumin (OVA) triggered higher OVA-specific CD8⁺ T cell responses than injection of recombinant adenovirus 5 expressing OVA. In mice with melanoma, a LCMV vector expressing the cancer epitope GD33 resulted in a greater reduction in tumor mass than adenovirus 5 or vaccinia virus vectors. Next steps could include further optimization of the vectors.</p> <p>SciBX 3(8); doi:10.1038/scibx.2010.263 Published online Feb. 25, 2010</p>	Patent and licensing status unavailable	<p>Flatz, L. <i>et al. Nat. Med.</i>; published online Feb. 7, 2010; doi:10.1038/nm.2104</p> <p>Contact: Daniel D. Pinschewer, University of Geneva, Geneva, Switzerland e-mail: daniel.pinschewer@gmx.ch</p> <p>Contact: Lukas Flatz, same affiliation as above e-mail: lukas.flatz@gmail.com</p>